Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Mephedrone, the New Designer Drug of Abuse: Pharmacokinetics, Pharmacodynamics and Clinical and Forensic Issues
Publication

Publications

Mephedrone, the New Designer Drug of Abuse: Pharmacokinetics, Pharmacodynamics and Clinical and Forensic Issues

Title
Mephedrone, the New Designer Drug of Abuse: Pharmacokinetics, Pharmacodynamics and Clinical and Forensic Issues
Type
Article in International Scientific Journal
Year
2012
Authors
Ribeiro, E
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Ricardo Jorge Dinis Oliveira
(Author)
FMUP
Journal
Vol. 25 No. 6
Pages: 111-117
ISSN: 0870-399X
Publisher: Ordem dos Medicos
Other information
Authenticus ID: P-002-C73
Abstract (EN): Mephedrone is a semisynthetic derivative of cathinone used as a drug of abuse. Similar to amphetamine, both in chemical structure and associated signs and symptoms, has gained popularity since 2007 and it is currently the sixth most abused drug in United Kingdom. It can be easily purchased by the internet or smart shops where it is advertised as a fertilizer for plants or bath salts, although such efficacy was never proved. This article aims to review the state-of-the-art literature of mephedrone, particularly its chemical structure, forms of presentation, pharmacokinetics, pharmacodynamics, acute intoxications, diagnosis and therapy of intoxications. Mephedrone is mainly sought for the following symptoms: euphoria, social disinhibition, empathy, and increased libido. However, its use is associated with several adverse effects on cardiovascular, gastrointestinal, neurological, psychiatric and genitourinary systems, among others. There are also reported cases of consumers who have developed tolerance and dependence after a regular abuse of mephedrone. Several deaths in the United Kingdom have been confirmed as being directly related to the consumption of mephedrone. Currently this drug is legally controlled in many countries, but little is known about its pharmacokinetics and pharmacodynamics. Most data comes only from users and health professional's reports and internet surveys. Recently, the Portuguese Law 13/2012, 26 of March, included mephedrone in the list of controlled substances, and therefore it is important to better understand this xenobiotic.
Language: Portuguese
Type (Professor's evaluation): Scientific
No. of pages: 7
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

Why should SARS-CoV-2 post-pandemic recovery funding be used to foster a physician-scientist program? (2020)
Another Publication in a National Scientific Journal
Barbosa Breda, J; Leal, I; Sousa, DC; Soares, CA
Why Should SARS-CoV-2 Post-Pandemic Recovery Funding Be Used to Foster a Physician-Scientist Program? (2020)
Another Publication in a National Scientific Journal
Barbosa Breda, J; Leal, I; Sousa, DC; Soares, CA
The 2019 novel Coronavirus (2019-NCoV): Novel virus, old challenges [O Novo Coronavírus (2019-nCoV): Novo Vírus, Desafios Antigos] (2020)
Another Publication in a National Scientific Journal
Duarte R; Furtado, I; Sousa, L; Carvalho, C
The Role of Pharmacovigilance in the COVID-19 Pandemic (2021)
Another Publication in a National Scientific Journal
Ferreira Da Silva, R; Ribeiro Vaz, I; Morato, M; Silva, AM; Polonia, J
The impact of the COVID-19 pandemic in the management of occupational injuries [O impacto da pandemia COVID-19 na prestação de cuidados de saúde em sinistralidade laboral] (2020)
Another Publication in a National Scientific Journal
Relvas Silva, M; Monteiro, E; Santos Carvalho, M; Negrão, P; Bettencourt, P; Neves, N; Ribeiro Silva, M

See all (575)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-18 at 15:57:31 | Privacy Policy | Personal Data Protection Policy | Whistleblowing